A61K 40/4274
Prostate associated antigens e.g. prostate stem cell antigen [psca]
Official title: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
A61K40/4274 (Prostate associated antigens e.g. prostate stem cell antigen [psca]) appears on 150 US grants and 361 published applications in this corpus.
Search patents in A61K- Granted patents
- 150
- Published applications
- 361
- Assignees
- 155
- Inventors
- 641
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 10 |
| 2003 | 1 | 8 |
| 2004 | 3 | 8 |
| 2005 | 2 | 4 |
| 2006 | 5 | 4 |
| 2007 | 2 | 2 |
| 2008 | 1 | 13 |
| 2009 | 1 | 4 |
| 2010 | 1 | 6 |
| 2011 | 3 | 11 |
| 2012 | 4 | 6 |
| 2013 | 4 | 9 |
| 2014 | 4 | 6 |
| 2015 | 5 | 16 |
| 2016 | 3 | 12 |
| 2017 | 5 | 13 |
| 2018 | 8 | 15 |
| 2019 | 4 | 19 |
| 2020 | 12 | 23 |
| 2021 | 11 | 32 |
| 2022 | 13 | 28 |
| 2023 | 10 | 31 |
| 2024 | 16 | 37 |
| 2025 | 15 | 24 |
| 2026 | 13 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-223 Jun 2026US 12,661,401 B2The Regents of the University of California
- Anti-steap1 antigen-binding protein1 Oct 2026US 2026/0297213 A1Amgen Inc.
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
- Prostate-specific membrane antigen targeted nf-kb p50-deficient immature myeloid cells27 Aug 2026US 2026/0248849 A1The Johns Hopkins University
- Synthetic antigen receptors for covalent immune recruiters and methods and uses thereof27 Aug 2026US 2026/0248852 A1McMaster University
- Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts27 Aug 2026US 2026/0248923 A1Purdue Research Foundation
Most cited
By later US patents
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy72US 5,788,963 APacific Northwest Cancer Foundation · 1998
- Method for isolating dendritic cells64US 5,643,786 AThe United States of America as represented by the Department of Health and Human Services · 1997
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes43US 9,220,728 B2Memorial Sloan Kettering Cancer Center · 2015
- Compositions and methods for the therapy and diagnosis of prostate cancer39US 6,800,746 B2Corixa Corporation · 2004